Author:
Badawy Sayed S.,Ahmed Yomna M.,Sultan M.A.
Subject
Spectroscopy,Analytical Chemistry
Reference48 articles.
1. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data, (n.d.). https://covid19.who.int/ (accessed January 16, 2023).
2. Y. Chen, Q. Liu, D. Guo, Emerging coronaviruses: Genome structure, replication, and pathogenesis, J. Med. Virol. 92 (2020) 2249–2249. 10.1002/JMV.26234.
3. Drug Trials Snapshots: DAKLINZA | FDA, (n.d.). https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-daklinza (accessed January 19, 2023).
4. C.Q. Sacramento, N. Fintelman-Rodrigues, J.R. Temerozo, A. de P.D. Da Silva, S. da S.G. Dias, C. dos S. da Silva, A.C. Ferreira, M. Mattos, C.R.R. Pao, C.S. de Freitas, V.C. Soares, L.V.B. Hoelz, T.V.A. Fernandes, F.S.C. Branco, M.M. Bastos, N. Boechat, F.B. Saraiva, M.A. Ferreira, S. Jockusch, X. Wang, C. Tao, M. Chien, W. Xie, R.K.R. Rajoli, C.S.G. Pedrosa, G. Vitoria, L.R.Q. Souza, L. Goto-Silva, M.Z. Guimaraes, S.K. Rehen, A. Owen, F.A. Bozza, D.C. Bou-Habib, J. Ju, P.T. Bozza, T.M.L. Souza, In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19, J. Antimicrob. Chemother. 76 (2021) 1874–1885. 10.1093/JAC/DKAB072.
5. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19;Eslami;J. Antimicrob. Chemother.,2020
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献